Phase II, Multi- center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the age of 60 Years or Unable to Receive Standard ABVD Chemotherapy
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma »